Strategies to tackle the challenges of external beam radiotherapy for liver tumors

Table 2 Prospective metastatic liver stereotactic body radiotherapy studies

Ref.	No. of patients	Dose (Gy/fraction)	Median follow-up (mo)	2-yr local control (%)
Herfarth et al[94], 2001	37	14-26 Gy/1	5.7	812
Hoyer et al[95], 2006	44	45 Gy/3	51.6	79
Kavanagh et al[96], 2006	36	60 Gy/3	19	93
Ambrosino et al[97], 2009	27	Median 36 (25-60) Gy/3	13	74 crude2
Rusthoven et al[62], 2009	47	36-60, 60 Gy/3	16	92
Lee et al[98], 2009	68	Median 41.8 Gy/6	10.8	712
Méndez Romero et al[93], 2006	171	30-37.5 Gy/2		86
Stintzing et al[99], 2010	361	24 Gy/l	21.3	872
Goodman et al[100], 2010	261	18-30 Gy/l	17	772
Rule et al[63], 2011	27	30 Gy/5	20	56
		50 Gy/5		89
		60 Gy/5		100
Janoray et al[101], 2014	56	45 Gy/3-60 Gy/3	12.5	642

¹Included hepatocellular patients;

²12-18 mo local control percentage.